Shots: Clover plans to initiate a global P-II/III efficacy trial with the S-Trimer COVID-19 vaccine candidate adjuvanted with CpG 1018 plus alum in the H1’2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021 Additionally, Clover discontinued their partnership with GSK to evaluate the S-Trimer vaccine candidate with GSK’s pandemic adjuvant […]Read More
The recent emergence of the coronavirus SARS-CoV-2 and the COVID-19 pandemic has spurred global healthcare and life sciences companies, as well as government agencies, to partner at unprecedented speed to develop vaccines, treatments, and tests This article covers the last four months of deal data provided by Chris Dokomajilar of DealForma Our team at PharmaShots […]Read More
1. Sanofi Receives the US FDA’s Approval for its MenQuadfi Meningococcal (MenACWY) Conjugate Vaccine Published: Apr 23, 2020 | Tags: Sanofi, Receives, US, FDA, Approval, MenQuadfi, Meningococcal, MenACWY, Conjugate Vaccine 2. Takeda to Divest Select OTC and Non-Core Assets in Europe to Orifarm for $670M Published: Apr 24, 2020 | Tags: Takeda, Divest, Select OTC and […]Read More
Shots: Shots: Valneva will utilize its technology and platform capabilities to develop an inactivated, whole virus vaccine candidate, VLA2001 against COVID-19 while Dynavax will provide its CpG 1018, the adjuvant used in HEPLISAV-B which is the FDA’s approved vaccine for hepatitis B Valneva is leveraging its platform that was used for IXIARO, a vaccine against […]Read More
Shots: The collaboration will assess the combination of Dynavax’s advanced adjuvant, CpG 1018 with Sinovac’s chemically inactivated coronavirus vaccine candidate Dynavax’s CpG 1018 is the adjuvant used in HEPLISAV-B, the FDA’s approved vaccine for hepatitis B. It was developed to increase HEPLISAV-B vaccine’s immune response CpG 1018 provides a technology and a safety database to […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
